NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Topadur Pharma AG

Topadur Pharma AG

Private
SchlierenHealthcare & Life Scienceshttps://topadur.com/

Last Round

Series C

Extension

Oct 1, 2024

Est. Valuation

$47.38M

Total Funding Raised

$25.75M

Company Overview

Topadur Pharma AG is a clinical-stage biopharmaceutical company that develops dual-acting small-molecule therapies to restore microcirculation and promote tissue regeneration for age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverysmall-molecule therapymicrocirculationtissue regenerationclinical-stage biotechout-licensingchronic wound caredermatologyalopecia treatmentdiabetic foot ulcersbiotech pipelinedrug developmentpharma partneringbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Topadur Pharma AG Comparables

Compare Topadur Pharma AG with similar companies based on industry and business-model similarity.

Topadur Pharma AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aurealis Therapeutics
79%
ElkosRx, LLC
78%
Ilya Pharma
73%

Topadur Pharma AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionOct 1, 2024
StrategicJun 6, 2024
GrantJan 5, 2024
GrantDec 20, 2023
GrantJun 7, 2022
Convertible Debt
Oct 1, 2020

Key People

Founding team and executive leadership

PD Dr. Matthias Schäfer

Chief Executive Officer

Executive Team

Topadur Pharma AG Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors grew 119% MoM.

  • Dec 20, 2023

    $1.2M grant received from Innosuisse and KIAT.

Topadur Pharma AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Topadur Pharma AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Topadur Pharma AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range16
Year Founded2015
Last FundingOct 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.